

ARTERIAL STIFFNESS IS ASSOCIATED WITH CORONARY ATHEROSCLEROSIS IN ASYMPTOMATIC PATIENTS WITH TYPE 2 DIABETES AND AGE AND SEX-MATCHED CONTROLS: A LONGITUDINAL STUDY

K. L. Funck¹, E. Laugesen^{1,2,3}, K. Øvrehus⁴, J.M. Jensen⁴, B.L. Nørgaard⁴, D. Dey⁵, T.K. Hansen¹, P.L. Poulsen¹

¹Department of Internal Medicine and Endocrinology, Aarhus University Hospital, Denmark, ²Department of Clinical Medicine, Aarhus University, ³The Danish Diabetes Academy, Odense, Denmark, ⁴Department of Cardiology, Aarhus University Hospital, Denmark, ⁵Biomedical Imaging Research Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA

INTRODUCTION

Arterial stiffness is a strong predictor of cardiovascular disease in patients with type 2 diabetes and persons without diabetes. The pathophysiological mechanisms behind this observation is, however, undetermined.

AIM

To investigate the association between baseline arterial stiffness and plaque volumes after 5 years follow-up in asymptomatic patients with type 2 diabetes and healthy controls

METHODS

Inclusion criteria

- Age > 18 years
- Patients: diagnosis of type 2 diabetes within 5 years of inclusion
- Healthy persons: Type 2 diabetes excluded by oral glucose tolerance test

Exclusion criteria

- Acute or chronic infectious disease
- End stage renal failure
- Prior or current cancer
- Contraindications to MRI (other purposes)

Main exposure variable

$PWV = \frac{D}{T}$

Arterial stiffness
Applanation tonometry, SphygmoCor® (carotid-femoral pulse wave velocity, PWV)


Main outcome variable

Coronary CT angiography

- Total plaque volume
- Calcified plaque volume
- Non-calcified plaque volume
- Low-density non-calcified plaque volume (lipid content)



Participant flow

Study program



RESULTS

Participant characteristics	Diabetes (n=43)	Controls (n=55)	p-value
Male n (%)	21 (48)	25 (45)	0.84
Age years (%)	Follow-up 64.7±9.5	62.5±9.7	0.26
Diabetes duration (years)	Follow-up 7.8±1.5	-	-
Follow-up (years)	5.5±0.4	5.3±0.3	<0.01
BMI (kg/m ²)	Baseline 28.6±4.4 Follow-up 28.3±3.9	25.7±3.1 26.3±3.4	<0.01 <0.01
HbA1c (mmol/mol)	Baseline 48±8 Follow-up 51±10	38±3 38±4	<0.01 <0.01
LDL (mmol/l)	Baseline 2.2±0.7 Follow-up 2.0±0.9	3.4±1.0 3.1±1.0	<0.01 <0.01
24 h systolic blood pressure (mmHg)	Baseline 126±11 Follow-up 122±12	124±11 124±13	0.24 0.55
Urin albumine creatinine ratio (mg/g) *	Baseline 0 (0-1) Follow-up 4 (0-9)	0 (0-1) 1 (0-3)	0.09 0.02
Antidiabetic medicine	Baseline 28 (64) Follow-up 35 (81)	0 (0) 1 (2)	<0.01 <0.01
(oral and GLP-1-analogs) n(%)	Baseline 5 (12) Follow-up 9 (21)	0 (0) 0 (0)	0.01 <0.01
Insulin n(%)	Baseline 25 (58) Follow-up 29 (67)	12 (22) 16 (30)	<0.01 <0.01
Antihypertensiva n(%)	Baseline 32 (74) Follow-up 36 (84)	8 (15) 11 (20)	<0.01 <0.01
Statin n(%)	Baseline 27 (63) Follow-up 33 (77)	1 (2) 10 (18)	<0.01 <0.01
Aspirin n(%)	Baseline 24 (56) Follow-up 25 (58)	29 (53) 29 (53)	0.84 0.68
Current or former smoker n(%)	Baseline 9.1±2.2 Follow-up 9.3±2.3	7.8±1.4 8.5±1.8	<0.01 0.06
PWV (m/s)			



CONCLUSION

PWV is strongly associated with volumes of low-density non-calcified plaques, a lipid-rich and high-risk component of coronary plaques.

